Endocrinology Research Analysis
Q2 2026 endocrinology coalesced around scalable metabolic therapeutics, tissue-resolved mechanisms, and precision diagnostics. Oral small-molecule GLP-1 receptor agonists advanced from phase 3b maintenance (orforglipron) to multicenter phase 2 efficacy (elecoglipron), consolidating a practice-shifting class beyond injectables. Randomized data operationalized difficult care pathways, including semaglutide as pharmacologic rescue after suboptimal bariatric outcomes and fibrosis-stratified cardiohe
Summary
Q2 2026 endocrinology coalesced around scalable metabolic therapeutics, tissue-resolved mechanisms, and precision diagnostics. Oral small-molecule GLP-1 receptor agonists advanced from phase 3b maintenance (orforglipron) to multicenter phase 2 efficacy (elecoglipron), consolidating a practice-shifting class beyond injectables. Randomized data operationalized difficult care pathways, including semaglutide as pharmacologic rescue after suboptimal bariatric outcomes and fibrosis-stratified cardiohepatic benefits in obesity without diabetes. Mechanistically, human-tissue work mapped metabolic state–dependent GLP-1 sites of action, while integrative CRISPR–QTL identified PDIA6/Golgi trafficking as a β-cell control axis. RNA biology linked impaired hepatic glycoRNA biogenesis to MASLD with in vivo rescue, and a Cell study reframed cumulative heat exposure as an endocrine risk via a skin–hypothalamus pathway. Precision tools matured with a proteome-informed CXCL10 blood test for LADA and a genotype-stratified melatonin RCT revealing acute β-cell harm in MTNR1B risk carriers.
Selected Articles
1. A skin-hypothalamus axis couples heat stress and metabolic dysfunction.
Preclinical mouse work shows that prior environmental heat exposure elevates skin-derived KLK14, which imprints hypothalamic LRRC7 signaling and heightens susceptibility to later diet-induced metabolic dysfunction, defining a durable skin–hypothalamus axis connecting climate heat to endocrine risk.
Impact: Introduces a causal peripheral-to-brain pathway linking cumulative heat exposure to long-term metabolic vulnerability, reframing environmental heat as an actionable endocrine risk factor.
Clinical Implications: Nomination of the KLK14–LRRC7 pathway highlights targets for risk mitigation; heat-exposure history may become part of metabolic risk assessment pending human validation.
Key Findings
- Prior heat increased susceptibility to later diet-induced metabolic dysfunction in mice.
- Heat stress elevated skin-derived KLK14 and imprinted hypothalamic LRRC7 signaling.
- Defines a durable skin–hypothalamus axis linking environmental heat to endocrine risk.
2. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
In a multicenter phase 2b RCT (n=404 treated), once-daily oral elecoglipron achieved clinically meaningful glycemic improvements with safety consistent with the GLP-1RA class, supporting advancement of the oral small-molecule GLP-1RA modality.
Impact: Substantiates efficacy and tolerability of an oral small-molecule GLP-1RA, accelerating a class that could transform access, adherence, and care delivery.
Clinical Implications: Positions oral GLP-1RAs as potential alternatives for patients unwilling or unable to use injectables, pending phase 3 confirmation and head-to-head comparisons.
Key Findings
- Randomized, double-blind, placebo-controlled phase 2b across nine countries (n=404 treated).
- Clinically meaningful glycemic reductions versus placebo with once-daily oral dosing.
- Safety and tolerability aligned with established GLP-1RA profiles.
3. Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
Glycosylated small RNAs are produced in human liver and reduced in MASLD due to downregulation of SIDT1 and DTWD2; AAV-mediated restoration of these mediators attenuated MASH in mice, nominating glycoRNA biogenesis as a biomarker source and therapeutic lever.
Impact: Defines a new RNA-based disease axis in metabolic liver disease with in vivo rescue, enabling biomarker discovery and pathway-specific intervention concepts.
Clinical Implications: Supports development of circulating glycoRNA readouts for noninvasive staging and motivates early-phase trials targeting glycoRNA biogenesis in MASLD.
Key Findings
- GlycoRNAs are synthesized in human liver and decreased in MASLD.
- Downregulation of SIDT1/DTWD2 drives glycoRNA loss and worsens lipid/inflammatory signaling.
- AAV restoration of SIDT1/DTWD2 attenuates MASH in mouse models.
4. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
In patients plateauing on injectable incretins, switching to once‑daily oral orforglipron preserved substantially more prior weight loss over 52 weeks than placebo, with a safety profile consistent with the GLP-1 class.
Impact: Operationalizes a scalable, adherence-friendly maintenance strategy that preserves injectable-induced weight loss using an oral agent.
Clinical Implications: Supports transitioning appropriate patients to oral maintenance when injections are impractical, with counseling on GI tolerability and the lack of head-to-head continuation data.
Key Findings
- Maintained ~75–79% of prior weight loss vs 37–49% with placebo over 52 weeks.
- Safety predominantly involved mild-to-moderate GI events, consistent with GLP-1 class.
- Addresses a practical need for oral maintenance after injectable-induced weight reduction.
5. Proinsulin regulators identified with CRISPR screen and in vivo mouse QTL mapping.
A genome-wide CRISPR screen and in vivo QTL mapping converge on Golgi trafficking as a central axis of proinsulin regulation, nominating PDIA6 as a top regulator whose perturbation reduces proinsulin accumulation and production via a UPR-independent mechanism.
Impact: Delivers a validated, mechanism-rich atlas of β-cell proinsulin control and nominates PDIA6/Golgi trafficking as actionable targets for β-cell dysfunction.
Clinical Implications: Suggests new β-cell–directed therapies to normalize the proinsulin/insulin balance and informs biomarker development tied to Golgi trafficking and PDIA6 activity.
Key Findings
- Genome-wide CRISPR identified 84 regulators of the intracellular proinsulin/insulin ratio.
- Golgi trafficking emerged as a primary organelle axis controlling proinsulin storage and levels.
- PDIA6 knockdown reduced Golgi/secretory granular proinsulin and impaired production via a UPR-independent mechanism.
6. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
In adults at least one year post-bariatric surgery with suboptimal weight loss, weekly semaglutide 2.4 mg achieved a mean −18.0% weight change at 68 weeks versus +0.4% with placebo, improving metabolic parameters and quality of life without new safety signals.
Impact: First high-quality double-blind RCT to establish pharmacologic rescue for post-bariatric nonresponders, addressing a major unmet need.
Clinical Implications: Supports semaglutide 2.4 mg as adjunctive therapy after suboptimal bariatric outcomes with monitoring for GI adverse events and long-term management planning.
Key Findings
- −18.0% mean weight change at 68 weeks versus +0.4% with placebo.
- No new safety signals beyond established GLP-1RA profiles.
- Metabolic and quality-of-life benefits versus placebo.
7. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
A prespecified analysis of the SELECT trial showed that semaglutide reduced MACE and improved fatty liver indices in obese adults without diabetes at increased fibrosis risk by FIB-4 criteria, with effects consistent across FIB-4 thresholds.
Impact: Extends RCT evidence for GLP-1RA cardiohepatic benefit in obesity stratified by noninvasive fibrosis scores, informing cross-disciplinary care.
Clinical Implications: Supports prioritizing semaglutide in obese patients with elevated FIB-4 even without diabetes, alongside imaging/biopsy confirmation as indicated.
Key Findings
- MACE reduction consistent across FIB-4 thresholds, including ≥1.3.
- Greater reductions in fatty liver index versus placebo over 104 weeks.
- Trend toward larger MACE reduction in the highest FIB-4 stratum.
8. Integrative proteogenomic and observational analysis identifies potential biomarkers for latent autoimmune diabetes in adults.
Proteome-wide Mendelian randomization and clinical validation nominate plasma CXCL10 as a causal, discriminative biomarker for LADA with ROC-AUC 0.838–0.889 and no major safety liabilities across phenome-wide analyses.
Impact: Combines causal inference and clinical discrimination to deliver a pragmatic blood test that could reduce LADA–T2D misclassification.
Clinical Implications: CXCL10 testing could aid early LADA recognition and guide immunologic/insulin-centered care pending multi-ancestry, prospective validation.
Key Findings
- Genetically higher plasma CXCL10 is causally associated with increased LADA risk.
- CXCL10 discriminated LADA from T2D/controls with ROC-AUC 0.838–0.889.
- Phenome-wide MR revealed no major safety liabilities.
9. Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
Human-tissue and translational work showed liraglutide enhances islet insulin secretion in glucose-intolerant donors but not normoglycemic donors; GLP-1R expression declines with rising HbA1c, and complementary brain versus islet mechanisms depend on metabolic state.
Impact: Defines a metabolic-state framework for GLP-1 efficacy and site of action in humans, enabling biomarker-driven patient selection for incretin therapy.
Clinical Implications: Supports stratifying GLP-1RA candidates by metabolic phenotype, motivating development and validation of response biomarkers.
Key Findings
- Liraglutide enhanced GSIS in islets from glucose-intolerant donors but not normoglycemic donors.
- GLP-1R mRNA declined with rising HbA1c in T2D donor islets.
- Complementary brain tanycyte-mediated versus islet-direct mechanisms depend on metabolic state.
10. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant.
A randomized, double-blind, placebo-controlled crossover trial (n=21) showed a single 5 mg dose of melatonin acutely worsened glucose tolerance and suppressed first-phase β-cell responsivity by about 40% in MTNR1B G-allele carriers, altering insulin feedback and preventing insulin-induced hypoglycemia.
Impact: Provides genotype-stratified mechanistic RCT evidence that a common supplement can acutely impair β-cell function in genetic risk carriers, informing precision counseling.
Clinical Implications: Clinicians should counsel at-risk patients on melatonin’s potential metabolic harm in MTNR1B carriers and consider genotype-informed choices for sleep aids pending chronic-use data.
Key Findings
- Melatonin worsened glucose tolerance in MTNR1B G-allele carriers but not noncarriers.
- First-phase β-cell responsiveness was reduced by ~40% under melatonin in carriers.
- Melatonin disrupted insulin feedback and prevented insulin-induced hypoglycemia in carriers.